-
1.发明申请公开(公告)号：US20090275546A1
公开(公告)日：2009-11-05
申请号：US12386002
申请日：2009-04-10
IPC分类号： A61K31/395 , C40B30/06 , C12N5/02
CPC分类号： G01N33/57419 , A61K31/00 , A61K31/395 , G01N33/57496 , G01N2333/485 , G01N2333/71 , G01N2800/52
摘要： Provided are methods of identifying a metabolic target in a cancer stem cell that include using a microarray to identify intracellular signaling networks within a population of cancer stem cells that respond to a growth factor for the stem cell. Also provided are methods of determining a personalized therapeutic regime that include receiving metabolic information relating to a cancer stem cell in a patient, determining the patient's personal criteria relevant to the therapeutic regime, and combining the metabolic and personal criteria. Also provided are a diagnostic test for establishing a personalized therapeutic regime for a colon cancer patient and methods of reducing colon cancer stem cells/treating colon cancer.
摘要翻译： 提供了确定癌症干细胞中的代谢靶标的方法，其包括使用微阵列来鉴定响应干细胞生长因子的癌干细胞群体内的细胞内信号传导网络。 还提供了确定个体化治疗方案的方法，其包括接收与患者中的癌干细胞相关的代谢信息，确定患者与治疗方案相关的个人标准，以及组合代谢和个人标准。 还提供了建立结肠癌患者的个性化治疗方案的诊断测试和减少结肠癌干细胞/治疗结肠癌的方法。
-
2.发明申请PHOSPHORYLATED C-ErbB2 AS A SUPERIOR PREDICTIVE THERANOSTIC MARKER FOR THE DIAGNOSIS AND TREATMENT OF CANCER 有权磷酸化C-ErbB2作为诊断和治疗癌症的高级预测性治疗标记公开(公告)号：US20110189173A1
公开(公告)日：2011-08-04
申请号：US13003206
申请日：2009-07-08
IPC分类号： A61K39/395 , C40B30/00 , G01N33/574 , A61K31/517 , C12Q1/48 , A61P35/00
CPC分类号： G01N33/57492 , A61K31/517 , A61K39/39558 , A61K2039/505 , C12Q1/6841 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , G01N1/30 , G01N33/54366 , G01N33/574 , G01N33/57415 , G01N2033/57403 , G01N2333/71 , G01N2800/52
摘要： The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.
摘要翻译： 本发明提供了可靠的方法来鉴定具有上皮起源癌症的受试者的亚群，其特征在于高水平的磷酸化c-erbB2，其与通过IHC或FISH测量的总c-erbB2的过表达不相关，用于选择 并包括c-erbB2直接治疗和治疗。 此外，本发明提供了一种可靠的方法，用于确定由IHC和FISH确定为c-erbB2阳性的具有上皮起源癌症的受试者是否应从c-erbB2直接治疗中排除， 磷酸化c-erbB2在上皮肿瘤组织中的显着水平。
-
公开(公告)号：US20100317740A1
公开(公告)日：2010-12-16
申请号：US12669833
申请日：2008-07-28
IPC分类号： A61K31/135 , G01N33/53 , A61P35/04
CPC分类号： G01N33/57415 , G01N2800/52
摘要： This invention relates, e.g., to a method for predicting the response of a subject having, or at risk of developing, breast cancer to Tamoxifen therapy. The method comprises measuring the amount of phosphorylation at residues S70 of Bcl-2, Y992 of EGFR, and/or Y527 of Src in a suitable sample from the subject, wherein a statistically significantly elevated level of phosphorylation at one or more of the three residues compared to a baseline value indicates that the subject is likely to be responsive to Tamoxifen therapy.
摘要翻译： 本发明涉及例如用于预测具有或有发展为乳腺癌患有他莫昔芬治疗的风险的受试者的反应的方法。 该方法包括在来自受试者的合适样品中测量在Bcl-2，Y992的EGFR和/或Src的残基S70处的磷酸化量，其中三个残基中的一个或多个的统计学上显着升高的磷酸化水平 与基线值相比表明受试者可能对他莫昔芬治疗有反应。
-
4.发明授权公开(公告)号：US06925389B2
公开(公告)日：2005-08-02
申请号：US09906661
申请日：2001-07-18
CPC分类号： G06F19/24 , G06F19/00 , G06F19/20 , G16H10/40 , G16H50/70 , Y10S707/99933 , Y10S707/99943
摘要： The invention describes a process for determining a biological state through the discovery and analysis of hidden or non-obvious, discriminatory biological data patterns. The biological data can be from health data, clinical data, or from a biological sample, (e.g., a biological sample from a human, e.g., serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate.), etc. which is analyzed to determine the biological state of the donor. The biological state can be a pathologic diagnosis, toxicity state, efficacy of a drug, prognosis of a disease, etc. Specifically, the invention concerns processes that discover hidden discriminatory biological data patterns (e.g., patterns of protein expression in a serum sample that classify the biological state of an organ) that describe biological states.
摘要翻译： 本发明描述了通过发现和分析隐藏或非明显的歧视性生物数据模式来确定生物学状态的过程。 生物数据可以来自健康数据，临床数据或来自生物样品（例如，来自人的生物样品，例如血清，血液，唾液，血浆，乳头吸入剂，滑液，脑脊液，汗液，尿液 ，粪便，眼泪，支气管灌洗液，拭子，针头精液，精液，阴道液，射精前剂量）等进行分析，以确定供体的生物学状态。 生物学状态可以是病理诊断，毒性状态，药物功效，疾病预后等。具体地，本发明涉及发现隐藏的歧视性生物数据模式的过程（例如，血清样品中的蛋白质表达模式，其分类 描述生物状态的器官的生物学状态）。
-
5.发明授权Phosphorylated C-ErbB2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer 有权磷酸化的C-ErbB2作为癌症诊断和治疗的优越预测因素公开(公告)号：US09086414B2
公开(公告)日：2015-07-21
申请号：US13003206
申请日：2009-07-08
IPC分类号： A61K39/395 , A01N43/48 , G01N33/53 , G01N33/543 , G01N33/574 , C12Q1/68 , A61K31/517 , G01N1/30 , A61K39/00
CPC分类号： G01N33/57492 , A61K31/517 , A61K39/39558 , A61K2039/505 , C12Q1/6841 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , G01N1/30 , G01N33/54366 , G01N33/574 , G01N33/57415 , G01N2033/57403 , G01N2333/71 , G01N2800/52
摘要： The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.
摘要翻译： 本发明提供了可靠的方法来鉴定具有上皮起源癌症的受试者的亚群，其特征在于高水平的磷酸化c-erbB2，其与通过IHC或FISH测量的总c-erbB2的过表达不相关，用于选择 并包括c-erbB2直接治疗和治疗。 此外，本发明提供了一种可靠的方法，用于确定由IHC和FISH确定为c-erbB2阳性的具有上皮起源癌症的受试者是否应从c-erbB2直接治疗中排除， 磷酸化c-erbB2在上皮肿瘤组织中的显着水平。
-
公开(公告)号：US09012240B2
公开(公告)日：2015-04-21
申请号：US13061507
申请日：2009-08-26
IPC分类号： G01N33/549 , G01N33/53 , G01N33/544 , G01N33/558 , G01N33/52 , G01N33/543
CPC分类号： G01N33/521 , G01N33/54333 , G01N33/54346
摘要： An immunoassay device incorporating porous polymeric capture nanoparticles within either the sample collection vessel or pre-impregnated into a porous substratum within fluid flow path of the analytical device is presented. This incorporation of capture particles within the immunoassay device improves sensitivity while removing the requirement for pre-processing of samples prior to loading the immunoassay device. A preferred embodiment is coreshell bait containing capture nanoparticles which perform three functions in one step, in solution: a) molecular size sieving, b) target analyte sequestration and concentration, and c) protection from degradation. The polymeric matrix of the capture particles may be made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. This device is useful for point of care diagnostic assays for biomedical applications and as field deployable assays for environmental, pathogen and chemical or biological threat identification.
摘要翻译： 提供了在分析装置的流体流动路径内将多孔聚合物捕获纳米颗粒结合到样品采集容器中或预浸渍到多孔基质内的免疫测定装置。 这种在免疫测定装置内的捕获颗粒的并入提高了灵敏度，同时在加载免疫测定装置之前消除了样品预处理的要求。 优选的实施方案是含有捕获纳米颗粒的芯壳诱饵，其在一个步骤中在溶液中进行三个功能：a）分子筛分，b）目标分析物螯合和浓缩，以及c）防止降解。 捕获颗粒的聚合物基质可以由具有结构单体和亲和单体的共聚物制成，亲和单体具有将分析物吸引到捕获颗粒的性质。 该设备可用于生物医学应用的护理点诊断分析以及环境，病原体和化学或生物威胁鉴定的现场部署测定。
-
7.发明申请EX VIVO THERAPEUTICS SCREENING OF LIVING BONE MARROW CELLS FOR MULTIPLE MYELOMA 审中-公开用于多发性骨髓瘤的生物骨髓细胞的筛查治疗公开(公告)号：US20110207627A1
公开(公告)日：2011-08-25
申请号：US13057978
申请日：2009-08-12
CPC分类号： G01N33/56972 , G01N33/5011 , G01N2333/70596 , G01N2510/00 , G01N2800/52
摘要： Methods of selecting a treatment for a patient with multiple myeloma are provided. Prior to commencing a treatment regime, bone marrow aspirates are isolated from a patient and incubated with one or more candidate therapeutics. The methods identify the therapy or combination of therapies most likely to yield the best results for a particular individual. In addition to improving clinical outcome, such theranostic evaluations dramatically reduce health care costs, by avoiding ineffective therapies. Screening assays for identifying treatments for multiple myeloma also are provided.
摘要翻译： 提供了选择多发性骨髓瘤患者的治疗方法。 在开始治疗方案之前，从患者中分离骨髓抽吸物并与一种或多种候选治疗剂一起温育。 该方法确定最有可能为特定个体产生最佳结果的治疗或疗法组合。 除了改善临床结果之外，这种诊断性评估通过避免无效疗法，大大降低了医疗保健成本。 还提供了用于鉴定多发性骨髓瘤治疗的筛选试验。
-
公开(公告)号：US20100203549A1
公开(公告)日：2010-08-12
申请号：US12676257
申请日：2008-09-05
CPC分类号： G01N33/96 , G01N33/5005
摘要： This invention relates, e.g., to a set of calibrants for determining the amount in a sample of an analyte (e.g., a protein, such as a protein that has been post-translationally modified), comprising a plurality of calibrants, which contain a range of amounts (e.g., defined amounts and/or serial dilutions) of the analyte, spanning the expected amount of the analyte in the sample. In each of the calibrants, a defined amount of the analyte is present in the same suitable, biological diluent (e.g., a cell or tissue lysate, or a bodily fluid). In one embodiment of the invention, the diluent reflects the same or a similar biological milieu (proteins, lipids, serum proteins, serum matrix proteins, etc.) as that in the sample in which the analyte to be measured is present. In embodiments of the invention, a single calibrant (e.g., a cell lysate) may comprise as many as hundreds of analytes, and can be used for the quantification of those hundreds of analytes in a sample. Methods are described for performing an assay (e.g. RPMA analysis), in which the calibrants of a set of calibrants of the invention are immobilized on each of the surfaces to which samples to be analyzed are immobilized, thereby providing an internal calibration curve for quantifying an RPMA assay.
摘要翻译： 本发明涉及例如用于确定分析物样品中的量（例如蛋白质，例如经翻译后修饰的蛋白质）的一组校准剂，其包含多个校准物，其包含范围 的分析物的量（例如，定义的量和/或连续稀释度），跨越样品中分析物的预期量。 在每个校准中，一定量的分析物存在于相同的合适的生物稀释剂（例如，细胞或组织裂解液或体液）中。 在本发明的一个实施方案中，稀释剂反映与待测分析物存在的样品中相同或相似的生物环境（蛋白质，脂质，血清蛋白，血清基质蛋白等）。 在本发明的实施方案中，单个校准物（例如，细胞裂解物）可以包含多达数百种分析物，并且可以用于量化样品中数百种分析物。 描述了用于进行测定（例如RPMA分析）的方法，其中将本发明的一组校准物的校准物固定在固定有待分析样品的每个表面上，从而提供内部校准曲线，用于量化 RPMA测定。
-
9.发明申请SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR MANIPULATING THERANOSTIC ASSAYS 审中-公开用于操纵治疗测定的系统，方法和计算机程序产品公开(公告)号：US20080243394A1
公开(公告)日：2008-10-02
申请号：US12057163
申请日：2008-03-27
IPC分类号： G01N33/569 , C12Q1/02 , G06F19/00
摘要： A theranostics technique for describing signaling pathway activity within a cellular or tissue sample may include analyzing a cellular sample to obtain sample quantitative values for a series of target protein modification levels reflected in a set of a plurality of protein biomarkers in the sample. The sample quantitative values may be compared to reference quantitative values for the same series of protein modification levels. The reference quantitative values may be statistically processed from a plurality of comparable samples. The sample quantitative values may be displayed in relation to the reference quantitative values in a way that may suggest a specific course of treatment.
摘要翻译： 用于描述细胞或组织样品中的信号传导途径活性的治疗技术可包括分析细胞样品以获得反映在样品中的多组蛋白质生物标志物的一组中的一系列靶蛋白修饰水平的样品定量值。 样品定量值可以与相同系列蛋白质修饰水平的参考定量值进行比较。 参考定量值可以从多个可比样品进行统计学处理。 样品定量值可以以可能表明具体治疗过程的方式相对于参考定量值显示。
-
公开(公告)号：US08835360B1
公开(公告)日：2014-09-16
申请号：US13455111
申请日：2012-04-24
IPC分类号： G01N33/50
CPC分类号： G01N33/5041
摘要： A method for selecting combinations of drugs for treatment of diseases that arise from deranged signaling pathways is disclosed. The method involves measuring the activity states for signaling proteins in a diseased cell and determining whether the activity states are different from the activity states observed for a reference cell such as a normal cell. Based on the observed differences, combinations of two or more drugs are selected to reduce these differences. Treatment of a subject with the combinations restores the activity states of the signaling proteins of the deranged disease-associated signaling pathways toward the activity states observed in the reference cell. Since the diseased cell and the reference cell can both be obtained from the same subject, combinations of drugs that specifically target patient-specific signaling derangements is possible.
摘要翻译： 公开了一种用于选择用于治疗由紊乱信号传导途径引起的疾病的药物组合的方法。 该方法包括测量患病细胞中的信号蛋白的活性状态，并确定活性状态是否与观察到的参考细胞例如正常细胞的活性状态不同。 基于观察到的差异，选择两种或更多种药物的组合以减少这些差异。 用组合治疗受试者恢复了与参考细胞中观察到的活动状态相关的紊乱疾病相关信号通路的信号蛋白的活性状态。 由于患病细胞和参照细胞都可以从相同的受试者获得，所以特别针对患者特异性信号紊乱的药物的组合是可能的。
-
-
-
-
-
-
-
-
-
搜索结果
92 条记录 (耗时 0.031 秒)
